Nanotechnology Now - Press Release: BioAlliance Pharma Presents Results for Its New Oral Chemotherapy Nanoparticle Innovation

Home > Press > BioAlliance Pharma Presents Results for Its New Oral Chemotherapy Nanoparticle Innovation

Abstract:
BioAlliance Pharma SA (Euronext Paris: BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, has presented its results on new oral chemotherapy nanoparticle formulation at the AAPS (American Association of Pharmaceutical Scientists) Annual Meeting in Los Angeles (November 8 to 12, 2009).

BioAlliance Pharma Presents Results for Its New Oral Chemotherapy Nanoparticle Innovation

Paris | Posted on November 13th, 2009

Oral chemotherapy is a great challenge and its success is expected to make a major breakthrough in cancer chemotherapy in the following years.

BioAlliance Pharma is developing an innovative proprietary nanoparticle technology offering new therapeutic solutions for oral administration in oncology. Using Sustained Release Nanoparticles (SRN) formulation, oral chemotherapy can maintain optimum drug plasma concentrations, providing prolonged exposure to cancer cells, then improving the efficacy and tolerance.

The data presented at the AAPS Meeting showed that the new oral formulation of irinotecan (IRN-SRN) entrapped into nanoparticles, allowing an oral delivery of IRN, significantly prolonged plasmatic half lives of IRN and SN-38, its active metabolite, compared to those observed after the intravenous administration of IRN, then increasing exposure to the active drug.

The IRN-SRN formulation tested in vivo in models of colorectal tumours was demonstrated to have similar efficacy on tumour growth inhibition and to be better tolerated than IRN administered IV.

"This oral nanoparticle innovation opens new ways to chemotherapy agents in cancer treatments," commented Dominique Costantini, President and CEO, BioAlliance Pharma.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2008 Reference Document filed with the AMF on April 7, 2009, which is available on the AMF website (www.amf-france.org) or on BioAlliance Pharma S.A.'s website (www.bioalliancepharma.com).

####

About BioAlliance Pharma
As a preferred partner for hospital-based specialists, BioAlliance Pharma is a company which develops and markets innovative products in France, especially in the fields of opportunistic infections and chemotherapy complications. In areas where medical needs are insufficiently met, our targeted approaches help overcome drug resistance and improve patient health & quality of life. BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs.

About the American Association of Pharmaceutical Scientists (AAPS)

The purpose of AAPS is to serve its membership, the pharmaceutical sciences, the biomedical and biotechnological community, the health professions, and the interest of public health. This is accomplished by providing open forums for the exchange and dissemination of scientific knowledge; by fostering the education and career growth of members and recognizing individual achievement; by influencing the formation of public policy relevant to health and related issues of public concern; and, by promoting the pharmaceutical sciences as they relate to health issues of public concern. Through its Annual Meeting, its conferences, workshops and symposia, through its print and online publications and other on-line initiatives, AAPS continues to offer vital benefits to the pharmaceutical scientists who constitute its membership.

Recognizing that modern science is conducted in an integrated fashion comprising many disciplines, AAPS seeks to foster the integration of those sciences related to discovery, design, analysis, development, production, quality control, safety, clinical evaluation, regulation, distribution and utilization of drugs and drug delivery systems. Thus, AAPS should serve as the primary focus and forum for interest in these disciplines.

For more information, please click here

Contacts:
BioAlliance Pharma SA
Dominique Costantini
+33-1-4558-7601
President and CEO

Nicolas Fellmann
+33-1-4558-7100
CFO

ALIZE RP
Caroline Carmagnol
+33-6-6418-9959